Key Highlights

  • Pulmonx (NASDAQ:LUNG) reports third-quarter 2026 results after the close on Tuesday, October 27, 2026, with consensus calling for a loss of USD 0.26 per share in published market data.
  • In the second quarter, reported on Wednesday, July 29, 2026, revenue was USD 22.8 million, the net loss narrowed and the shares jumped about 14.4% as results beat consensus estimates.
  • The company sells the Zephyr Endobronchial Valve for severe emphysema, so revenue depends on procedure volumes, hospital adoption and reimbursement rather than on a broad consumer or macro cycle.
  • The Federal Reserve decides on Wednesday, October 28, 2026, a day after the report, which matters for small loss-making medical device companies that are sensitive to financing costs.

The Setup and the Last Guidance

Pulmonx (NASDAQ:LUNG) is a commercial-stage medical technology company, and it is scheduled to report third-quarter results after the market close on Tuesday, October 27, 2026. Consensus estimates call for a loss of USD 0.26 per share. In the second quarter, announced in the company's release of Wednesday, July 29, 2026, revenue was USD 22.8 million and the net loss narrowed from the prior year. A published call summary describes the quarter as ahead of consensus estimates, and the stock rose about 14.4% afterwards. The full-year revenue and gross margin outlook set at that time is the benchmark for this report. Results cannot be known in advance.

Why Procedure Volumes and Cash Burn Decide the Reaction

Pulmonx (NASDAQ:LUNG) sells the Zephyr Valve, a small implant placed by bronchoscope to reduce trapped air in the lungs of patients with severe emphysema. Revenue therefore follows the number of treated patients, which depends on referrals from pulmonologists, the capacity of hospital procedure suites and payer coverage. Because the business is still loss-making, investors judge two things together: revenue growth, especially in the United States, and the pace at which the company burns cash. Gross margin matters as a proxy for scale, since a higher margin means each additional valve contributes more to covering fixed costs. The narrowing loss in the second quarter set a higher bar for the third quarter. Sector read-across comes from larger respiratory and surgical device companies reporting in the same season.

Risks and What to Watch

The bull case is revenue at or above the second-quarter level of USD 22.8 million, a further narrowing of the loss and a reiterated or raised full-year outlook, which after a 14.4% gain in July could extend the recovery in the shares. The bear case is a slower procedure ramp, a lower gross margin or a cut to the full-year outlook, which small-capitalisation device shares have often punished sharply because the market treats guidance as the main signal. Investors should watch United States growth, gross margin, operating expenses, cash and the company's equity needs. The dated events are the release on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Pulmonx (NASDAQ:LUNG) reports against a USD 0.26 loss estimate, but revenue growth, gross margin and the full-year outlook are likely to move the shares more than the loss itself. A second-quarter beat has lifted expectations, so reiterated guidance may be needed to hold the gain. The next catalysts are the after-close release on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026. Consensus figures are estimates, not guarantees, and this is not investment advice.